Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214837 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
A Phase 3 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 3
- Development phase
- 751
- Enrollment target
NCT01214837 is a Phase 3 study that has completed, run by Novartis Vaccines. The registered enrollment target is 751 participants.
The verdict
NCT01214837, a Phase 3 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 751 participants
- Enrollment target
Study Summary
The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
Interventions
- BIOLOGICAL MenACWY-CRM
- BIOLOGICAL Routine Vaccines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 751 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214837
The ClinicalTrials.gov registry entry for NCT01214837 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 751 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MenACWY-CRM is the first listed.
NCT01214837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01214837 about?
NCT01214837 is a clinical study titled "Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life". The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
What is the current status of trial NCT01214837?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 751 participants. The study started on 2010-10. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01214837?
The interventions under investigation include: MenACWY-CRM (BIOLOGICAL), Routine Vaccines (BIOLOGICAL).
Who is sponsoring clinical trial NCT01214837?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.